Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777708
Status:
TERMINATED
Last Update Posted:
2023-03-24
First Post:
2021-02-25
Brief Title:
BO-112 and Pembrolizumab for the Treatment of PD-1PD-L1 Refractory Liver Cancer
Sponsor:
Organization:
Jonsson Comprehensive Cancer Center
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
1
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| EARLY_PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: